

(FILE 'HOME' ENTERED AT 17:26:39 ON 21 MAY 2001)

FILE 'MEDLINE' ENTERED AT 17:26:45 ON 21 MAY 2001
L1 22797 S MULTIPLE (1W) SCLEROSIS
L2 0 S L1 AND (B (1W) CELL (1W) DEPLETION)
L3 5 S L1 AND CD20
L4 0 S NELSON MB/AU
L5 390 S NELSON M/AU
L6 0 S L5 AND CD20
L7 0 S L5 AND (B (1W) CELL (1W) DEPLETION)
L8 2632 S L1 AND ANTIBODY
L9 0 S L5 AND (B (1W) LYMPHOCYTE (1W) DEPLETION)
L10 0 S L1 AND (B (1W) LYMPHOCYTE (1W) DEPLETION)
L11 0 S L1 AND L5
L12 138 S L8 AND (B (1W) LYMPHOCYTE)
L13 5 S L12 AND DEPLETION
L14 24854 S L1 OR EAE
L15 3190 S L14 AND ANTIBODY
L16 81 S L15 AND DEPLET?
L17 0 S L14 AND RITUXIMAB
L18 198 S RITUXIMAB
L19 124 S L18 AND CD20
L20 67 S L18 AND CHIMERIC

FILE 'REGISTRY' ENTERED AT 17:45:25 ON 21 MAY 2001

FILE 'HOME' ENTERED AT 17:46:56 ON 21 MAY 2001

FILE 'REGISTRY' ENTERED AT 17:49:39 ON 21 MAY 2001

L21 1 S RITUXIMAB

FILE 'CAPLUS' ENTERED AT 17:52:03 ON 21 MAY 2001

L22 77 S L21
L23 12700 S L22 AND MS OR EAE OR SCLEROSIS
L24 1 S L22 AND (MS OR EAE OR SCLEROSIS)

FILE 'BIOSIS' ENTERED AT 17:53:50 ON 21 MAY 2001

L25 253 S L21
L26 0 S L25 AND (MS OR EAE OR SCLEROSIS)

FILE 'REGISTRY' ENTERED AT 17:54:22 ON 21 MAY 2001

FILE 'DRUGPAT' ENTERED AT 17:55:01 ON 21 MAY 2001

L27 37 S L21
L28 0 S L21 AND (MS OR EAE OR SCLEROSIS)

FILE 'MEDLINE' ENTERED AT 17:55:36 ON 21 MAY 2001

L3 ANSWER 4 OF 5 MEDLINE
ACCESSION NUMBER: 92147284 MEDLINE
DOCUMENT NUMBER: 92147284 PubMed ID: 1783458
TITLE: Preferential reductions in lymphocyte sub-populations induced by monthly pulses of chlorambucil: studies in patients with chronic progressive **multiple sclerosis**.
AUTHOR: Chiappelli F; Myers L W; Ellison G W; Liao D; Fahey J L
CORPORATE SOURCE: Psychoneuroimmunology Program, University of California, Los Angeles 90024.
CONTRACT NUMBER: AI 07126 (NIAID)
AI 15332 (NIAID)
SOURCE: INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, (1991) 13 (5) 455-61.
Journal code: GRI; 7904799. ISSN: 0192-0561.
PUB. COUNTRY: ENGLAND: United Kingdom
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199203
ENTRY DATE: Entered STN: 19920405
Last Updated on STN: 19920405
Entered Medline: 19920317
AB Thirty-three patients with chronic progressive **multiple sclerosis** (MS) were assigned to intervention groups receiving monthly pulses of chlorambucil (CB) for about one year. The monthly doses ranged from 0.4 to 1.5 mg/kg. Administration of CB resulted in preferential reduction in different lymphocyte subsets which was dose-
and time-dependent. The number of B-cells (**CD20**) decreased more rapidly than NK-cells (CD16, CD56, CD16+CD56+) or T-cell (CD3) and T-cells subsets (CD4 and CD8). At 1.2 mg/kg, CB administration resulted in a preferential drop of T-suppressor/cytotoxic cells (CD8) compared with T-helper cells (CD4), and of the less mature "virgin" CD4 cells (CD4+CD45RA+) compared with "memory" CD4 cells (CD4+CD45RA-). The expression of activation markers (transferrin receptor, CALLA, HLA-Dr and CD38[OKT10]) within CD4, CD8 or **CD20** lymphocytes was not altered by CB administration. Our data, which show that CB administration results in a preferential fall in B-cell numbers, contrast with the effects of long-term administration of the related immunosuppressive drugs, azathioprine and cyclophosphamide.

L20 ANSWER 4 OF 67 MEDLINE
ACCESSION NUMBER: 2001194878 MEDLINE
DOCUMENT NUMBER: 21117639 PubMed ID: 11226006
TITLE: **Rituximab**: an insider's historical perspective.
AUTHOR: Grillo-Lopez A J
CORPORATE SOURCE: Medical and Regulatory Affairs Division, IDEC
Pharmaceuticals Corporation, San Diego, CA 92121, USA.
SOURCE: SEMINARS IN ONCOLOGY, (2000 Dec) 27 (6 Suppl 12) 9-16.
Journal code: UN5; 0420432. ISSN: 0093-7754.
PUB. COUNTRY: United States
Historical
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200104
ENTRY DATE: Entered STN: 20010410
Last Updated on STN: 20010410
Entered PubMed: 20010227
Entered Medline: 20010405

AB **Rituximab** (Rituxan; Genentech, Inc, South San Francisco, CA and IDEC Pharmaceutical Corporation, San Diego, CA) is a unique monoclonal antibody for the treatment of non-Hodgkin's lymphoma. This **chimeric** mouse/human antibody was discovered in 1991 at IDEC Pharmaceuticals' laboratories, where the antibody was genetically engineered and produced utilizing high-yield expression systems. It is a human IgG1 kappa antibody with mouse variable regions isolated from a murine anti-CD20 antibody, IDEC-2B8, that binds with high affinity to cells expressing the CD20 antigen found on the surface of malignant and normal B cells, but not on other normal tissues. It mediates complement-dependent cell lysis in the presence of human complement, and antibody-dependent cellular cytotoxicity with human effector cells. Also, it has been shown to induce apoptosis and to sensitize chemoresistant human lymphoma cell lines *in vitro*. Clinical development was expedited (3 years) with the first patient entered in phase I trials in March 1993 and the last patient entered in the phase III study in March 1996. IDEC Pharmaceuticals began a collaboration with Genentech, Inc in March 1995 and with F. Hoffman-LaRoche (Nutley, NJ) shortly thereafter. Marketing approval was granted by the US Food and Drug Administration on November 26, 1997 (and by the European Union on June 2, 1998) for the indication

of relapsed or refractory, CD20-positive, B-cell, low-grade or follicular non-Hodgkin's lymphoma. **Rituximab** is the first therapeutic monoclonal antibody approved for the treatment of cancer and the first single agent approved specifically for therapy for a lymphoma.

Substantial research has been performed over the past 8 years to further the understanding of this novel therapeutic. Nevertheless, much remains to be accomplished in key areas such as mechanism of action and resistance, combinations with chemotherapy, biologics and radiotherapy/radioimmunotherapy, role within multimodality regimens, and nonmalignant applications. Research conducted in the coming years should be targeted toward resolving these important issues.

L24 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 2000:814347 CAPLUS
 DOCUMENT NUMBER: 133:361915
 TITLE: Treatment of autoimmune diseases with antagonists
 which bind to B cell surface markers
 INVENTOR(S): Curd, John G.; Kunkel, Lori A.; Grillo-Lopez, Antonio
 J.
 PATENT ASSIGNEE(S): Genentech, Inc., USA; Idec Pharmaceuticals, Inc.
 SOURCE: PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000067796	A1	20001116	WO 2000-US40018	20000504
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 1999-133018 P 19990507
 US 1999-139621 P 19990617

AB The present invention concerns treatment of autoimmune diseases with
 antagonists, e.g. antibodies, which bind to B cell surface markers, such
 as CD19 or CD20.

REFERENCE COUNT: 5
 REFERENCE(S):
 (1) Johnston, P; BLOOD, PART 2 1999, V94(10, SUPP 1),
 P4386
 (2) Lee, E; BLOOD 1998, V92(9), P3490 CAPLUS
 (3) Mow, B; BLOOD, PART 2 1999, V94(10, SUPP 1),
 CAPLUS
 (4) Scheuermann, R; US 5686072 A 1997 CAPLUS
 (5) Univ Leland Stanford Junior; WO 9503770 A 1995
 CAPLUS

P3526

[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#) | [Search Form](#) | [Posting Counts](#) | [Show S Numbers](#) | [Edit S Numbers](#) | [Preferences](#)**Search Results -**

Terms	Documents
5736137.pn.	2

Database: [US Patents Full-Text Database](#)
[US Pre-Grant Publication Full-Text Database](#)
[JPO Abstracts Database](#)
[EPO Abstracts Database](#)
[Derwent World Patents Index](#)

[IBM Technical Disclosure Bulletins](#)

5736137.pn.

[Clear](#)**Search History****Today's Date:** 5/21/2001

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,DWPI	5736137.pn.	2	<u>L2</u>
USPT,PGPB,DWPI	sclerosis and CD20	80	<u>L1</u>



PubMed	Nucleotide	Protein	Genome	Structure	PopSet	Taxonomy	OMIM	
Search	PubMed	<input checked="" type="checkbox"/> for				Preview	Go	Clear
			Limits	Preview/Index	History	Clipboard		

Entrez PubMed

- Search History will be lost after one hour of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.

NEW	Search	Most Recent Queries	Time	Result
PubMed Services	#12 Link to PubMed from (11205153)		07:34:42	100
	#9 Link to PubMed from (11332657)		07:32:32	101
	#1 Search multiple sclerosis review		07:30:23	3076

[Clear History](#)

Related Resources

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)

PubMed	Nucleotide	Protein	Genome	Structure	PopSet	Taxonomy	OMIM
Search PubMed	<input type="text"/> for				<input type="button" value="Go"/>	<input type="button" value="Clear"/>	
				Limits	Preview/Index	History	Clipboard

Entrez PubMed

NEW

Display	Summary	<input type="button" value="Sort"/>	<input type="button" value="Save"/>	Text	Order	Remove from Clipboard
Show:	20	<input type="button" value="▼"/>	Items 1-10 of 10			

PubMed Services

Related Resources

- 1: [Clegg A, Bryant J.](#) Relate
 Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost-effectiveness.
Expert Opin Pharmacother. 2001 Apr;2(4):623-39.
 PMID: 11336612 [PubMed - in process]

- 2: [O'Connor KC, Bar-Or A, Hafler DA.](#) Relate
 The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis.
J Clin Immunol. 2001 Mar;21(2):81-92.
 PMID: 11332657 [PubMed - in process]

- 3: [Gironi M, Bergami A, Brambilla E, Ruffini F, Furlan R, Comi G, Martino G.](#) Relate
 Immunological markers in multiple sclerosis.
Neurol Sci. 2000;21(4 Suppl 2):S871-5. Review.
 PMID: 11205366 [PubMed - indexed for MEDLINE]

- 4: [Berger T, Reindl M.](#) Relate
 Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis.
J Neural Transm Suppl. 2000;(60):351-60. Review.
 PMID: 11205153 [PubMed - indexed for MEDLINE]

- 5: [Campbell JD, HayGlass KT.](#) Relate
 T cell chemokine receptor expression in human Th1- and Th2-associated diseases.
Arch Immunol Ther Exp (Warsz). 2000;48(6):451-6. Review.
 PMID: 11197598 [PubMed - indexed for MEDLINE]

- 6: [Donoghue S, Greenlees C.](#) Relate
 Drugs in development for the treatment of multiple sclerosis: antigen non-specific therapy update.
Expert Opin Investig Drugs. 2000 Jan;9(1):167-71. Review.
 PMID: 11060669 [PubMed - indexed for MEDLINE]

- 7: [Ewing C, Bernard CC.](#) Relate
 Insights into the aetiology and pathogenesis of multiple sclerosis.
Immunol Cell Biol. 1998 Feb;76(1):47-54. Review.
 PMID: 9553776 [PubMed - indexed for MEDLINE]

8: [Genain CP, Cannella B, Hauser SL, Raine CS.](#)

[Relate](#)

Identification of autoantibodies associated with myelin damage in multiple sclerosis.

Nat Med. 1999 Feb;5(2):170-5.

PMID: 9930864 [PubMed - indexed for MEDLINE]

9: [Wekerle H.](#)

[Relate](#)

Remembering MOG: autoantibody mediated demyelination in multiple sclerosis?

Nat Med. 1999 Feb;5(2):153-4. No abstract available.

PMID: 9930860 [PubMed - indexed for MEDLINE]

10: [Liblau RS, Fontaine B.](#)

[Relate](#)

Recent advances in immunology in multiple sclerosis.

Curr Opin Neurol. 1998 Aug;11(4):293-8. Review.

PMID: 9725073 [PubMed - indexed for MEDLINE]

Display	Summary	▼	Sort	▼	Save	Text	Order	Remove from Clipboard
Show:	20	▼	Items 1-10 of 10				0	

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)